Key result
AYPGKF and thrombin activate Src and p38-MAPK pathways via PAR-4 in cardiomyocytes, distinct from PAR-1.
Answers are grounded in this paper and cite their sources.
PAR-4 exhibits a unique signaling phenotype in cardiomyocytes involving Src and EGFR transactivation, which may influence cardiac remodeling during inflammation.
Protease-activated receptor (PAR)-4 is a low affinity thrombin receptor with slow activation and desensitization kinetics relative to PAR-1. This study provides novel evidence that cardiomyocytes express functional PAR-4 whose signaling phenotype is distinct from PAR-1 in cardiomyocytes. AYPGKF, a modified PAR-4 agonist with increased potency at PAR-4, activates p38-mitogen-activated protein kinase but is a weak activator of phospholipase C, extracellular signal-regulated kinase, and cardiomyocyte hypertrophy; AYPGKF and thrombin, but not the PAR-1 agonist SFLLRN, activate Src. The observation that AYPGKF and thrombin activate Src in cardiomyocytes cultured from PAR-1(-/-) mice establishes that Src activation is via PAR-4 (and not PAR-1) in cardiomyocytes. Further studies implicate Src and epidermal growth factor receptor (EGFR) kinase activity in the PAR-4-dependent p38-mitogen-activated protein kinase signaling pathway. Thrombin phosphorylates EGFRs and ErbB2 via a PP1-sensitive pathway in PAR-1(-/-) cells that stably overexpress PAR-4; the Src-mediated pathway for EGFR/ErbB2 transactivation underlies the protracted phases of thrombin-dependent extracellular signal-regulated kinase activation in PAR-1(-/-) cells that overexpress PAR-4 and in cardiomyocytes. These studies identify a unique signaling phenotype for PAR-4 (relative to other cardiomyocyte G protein-coupled receptors) that is predicted to contribute to cardiac remodeling and influence the functional outcome at sites of cardiac inflammation.
No takes yet. Share an insight, caveat, or question.
Sabri et al. (2003) studied this question. AYPGKF and thrombin vs. SFLLRN (PAR-1 agonist) was evaluated on Src and p38-MAPK activation, EGFR/ErbB2 transactivation. AYPGKF and thrombin activate Src and the p38-MAPK signaling pathway via PAR-4 in cardiomyocytes, identifying a unique signaling phenotype distinct from PAR-1.
Synapse has enriched 10 related papers. Consider them for comparative context: